Navigation Links
Rigel to Present at the Oppenheimer 19th Annual Healthcare Conference
Date:10/29/2008

SOUTH SAN FRANCISCO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, Rigel's executive vice president and chief operating officer, will present a company overview at the Oppenheimer 19th Annual Healthcare Conference on Monday, November 3 at 3:20 p.m. EST at The Waldorf Astoria Hotel in New York City.

To access the live audio webcast or the subsequent archived recording, log on to http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Contact: Ryan Maynard

Phone: 650.624.1284

Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Rigel to Webcast Investor Update on October 27, 2008
2. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
3. Rigel to Present at Collins Stewart Growth Conference
4. Rigel Announces First Quarter 2008 Financial Results
5. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
6. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
7. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
8. Rigel Announces Offering of 4,000,000 Shares of Common Stock
9. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP
10. Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
11. Rigel Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... An increase in wetter weather in ... plants, and along with that; a humdinger of an allergy season. A relief from ... an increase in misery-causing grass and weed pollen. , “Our patients have been ...
(Date:6/25/2017)... ... 25, 2017 , ... With a heatwave currently bearing down on Northern California pushing temperatures to ... Being swimsuit ready is easy with laser hair removal. , The process of summer ... burdensome routine when all you want to do is get out, dive in and cool ...
(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
(Date:6/24/2017)... Ronkonkoma, New York (PRWEB) , ... June 24, ... ... now joined the Dental365 family. Located at 217 Portion Road in Lake Ronkonkoma, ... also open evenings and weekends so that visits to the dentist fit into ...
(Date:6/24/2017)... ... 24, 2017 , ... Doorknobs are for convenience, deadbolts are for security. , ... dog or having an alarm system installed. But unless there is a working deadbolt ... owner of TX Premier Locksmith in Killeen, TX says: “In the majority of home ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... BRUSSELS and INDIANAPOLIS , ... people are living with diabetes. In a further effort ... benefit people affected by this condition, the International Diabetes ... LLY ) have come together for the second ... Environments and Systems programme (BRIDGES 2), reaffirming their commitment ...
(Date:6/7/2017)... , June 7, 2017  Novavax, Inc., (Nasdaq: ... two Phase 2 trials of its RSV F protein recombinant ... bearing age have been published in the journal ... been shared in prior scientific conferences). The Company previously announced ... 2014. Novavax is developing the RSV F Vaccine with the ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq: ... care, today announced new findings demonstrating positive biochemical outcomes ... System One™. The data will be presented at ... Madrid, Spain . ... Improve Home Dialysis Network in Europe ...
Breaking Medicine Technology: